Porsolt SAS and KWS BioTest Ltd combine forces
PRESS RELEASE
Porsolt SAS and KWS BioTest Ltd combine forces to provide comprehensive preclinical evaluation in the area of inflammation and immunology.
Paris, France and Bristol, UK 4th May 2010 – Porsolt and KWS announced today they have entered into a co-marketing agreement to promote a common catalogue of preclinical tests in the area of inflammation and immunology. The partnership enables Porsolt and KWS to deliver a complete cascade of tests to evaluate drug candidates, from simple screening assays to more complex models with high translational value. The combination of the expertise of skilled teams of scientists working in both companies will provide customers with integrated solutions for highly efficient discovery & development of their drug candidates in these important therapeutic domains with large unmet needs.
Dr. Martine Lemaire, Senior Director, Commercial & Business Development of Porsolt said, "Porsolt is delighted to be entering into this strategic partnership with KWS. The combination of Porsolt’s expertise in functional readouts with KWS’s expertise in bioanalysis will bring a tremendous added-value to the models we are offering to our customers. This partnership enables us to expand our capabilities in the area of inflammation and immunology, answering the needs expressed by our customers. We are convinced that the synergy between our two companies will benefit our customers. Indeed, it is clear that KWS share our core values of scientific excellence and focusing on customer needs.”
Professor Neil Williams, Director of Science and founder of KWS added, “This is a great step forward for both companies, but most importantly, it will allow pharmaceutical and biotechnology companies to access the breadth of expertise
that they require to design and carry out efficacy testing of their drugs in this important therapeutic area. Both companies have a history of adding real value to drug development programmes and are focused on developing new models and assays to better predict drug efficacy in man. KWS combines immunology expertise with an understanding of pathology and clinical disease processes, and the fit with the functional expertise for which Porsolt is renowned is very exciting”.
About Porsolt SAS (Porsolt & Partners Pharmacology)
Porsolt is a long established preclinical CRO, having started operations in 1984 under the name ITEM-Labo. Porsolt has obtained an international reputation for expertise in physio-pathological models, customized procedures and tailored solutions for discovering treatments of psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, and metabolic and eating disorders. Porsolt also offers services for safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration in full compliance with GLP (ICH S7), including full assessment of arrhythmogenic risk and abuse and dependence liability.
Porsolt is located in France with facilities in Paris and Laval. For additional information about the organisation, please visit www.porsolt.com or email us at contact@porsolt.com
About KWS BioTest Ltd.
KWS BioTest Ltd was established in 2004 as a CRO, bringing together internationally renowned scientific expertise in a commercially managed environment. KWS offers a wide range of preclinical services from primary and secondary screens through to complex disease models in the areas of infection, inflammation, autoimmunity, allergy, pain and metabolic disease. In all of these areas KWS combines analysis of traditional disease parameters with bioanalytical and pathology services in order to work with our customers to design and deliver bespoke programmes that meet with their expectations.
KWS is based in the UK with facilities in Bristol and Sittingbourne. For additional information about the company, please visit www.kwsbiotest.co.uk or email us at pr@kwsbiotest.co.uk